18 September 2020
Allen & Overy advises Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam® Assets
Advising firms
Deal team
17 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Paul Burns Lead | Allen & Overy | Partner | Corporate and M&A | Not stated |
| Caitlin Hanley | Allen & Overy | Associate | Not stated | New York |
| Lucy Cai | Allen & Overy | Associate | Not stated | New York |
| Matthew Appleton | Allen & Overy | Partner | Corporate | London |
| Jim Ford | Allen & Overy | Partner | Corporate | London |
| Gareth Irving | Allen & Overy | Counsel | Not stated | Not stated |
| Megan McMellon | Allen & Overy | Associate | Not stated | Not stated |
| Ben Brooks | Allen & Overy | Associate | Not stated | Not stated |
| Magnus Yadi | Allen & Overy | Associate | Not stated | Not stated |
| Marta Guardiola | Allen & Overy | Associate | Not stated | Madrid |
| Dominik Stühler | Allen & Overy | Partner | Private Equity | Munich |
| Kai Terstiege | Allen & Overy | Counsel | Not stated | Munich |
| Keren Livneh | Allen & Overy | Senior associate | IP | New York |
| Dr Heike Weber | Allen & Overy | Partner | Tax | Frankfurt |
| John Hibbard | Allen & Overy | Associate | Tax | New York |
| Dr René Galle | Allen & Overy | Counsel | Antitrust | Hamburg |
| Philipp Steinhaeuser | Allen & Overy | Associate | Antitrust | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Apax Partners and its portfolio company Neuraxpharm GroupBuy-side
- Counterparties
- Takeda Pharmaceutical Company Limited (Sell-side)